pMHC Antibody Discovery
All of the advantages of human monoclonal antibodies with the ability to target intracellular proteins enabled by our revolutionary technology platform, Retained DisplayTM (ReD).
ReD: Targeting Intracellular Proteins
Existing antibody-based therapies such as bispecific antibodies and CAR-T cells target proteins expressed on the cell surface. Myrio’s ReD platform is enabling antibody-based therapeutics to be developed against a much broader range of targets including those that are expressed intracellularly. While antibodies cannot access the interior of the cell, Myrio’s scFvs can target the same antigen presentation pathway used by T-cells, where fragments of intracellular proteins are presented on the cell surface. Myrio’s scFvs will dramatically increase the approaches to treating solid tumors, persistent viral infections, and certain autoimmune diseases.
Latest news
Myrio Therapeutics awarded CUREator grant for pandemic preparedness research
May 31, 2023
31 May 2023, MELBOURNE, Australia – Australia’s sovereign pandemic preparedness has received a boost with Myrio Therapeutics Pty Ltd (Myrio), a…
Myrio Therapeutics data published in Nature: unlocking new targets for antibody-based therapies
November 4, 2021
Myrio Therapeutics Pty Ltd (Myrio) today announced ground-breaking findings published in the Journal Nature. The study, titled Therapeutic Targeting…
CoVIC consortium publishes Global study on variant-resistant SARS-CoV-2 epitopes in Science
September 23, 2021
Myrio is proud to be part of the global CoVIC consortium, providing antibodies in the fight against COVID-19. The results of the consortiums work…